InvestorWire NewsRoom

Article

Brain Scientific Inc. (BRSF) Poised to Offer Brain Monitoring Solution as Research Shows Neurological Findings in COVID-19 Long-Haulers
June 10, 2021

Brain Scientific Inc. (BRSF) Poised to Offer Brain Monitoring Solution as Research Shows Neurological Findings in COVID-19 Long-Haulers

  • Most extensive research to date reports significant neurological problems in patients who suffered from so-called long-haul COVID-19
  • Neurological issues range from mild to more severe such as cognitive impairment, which affects around 20% of these patients
  • BRSF appears poised to be part of the solution as long-haulers need monitoring so that doctors can assess if they have neurological disorders

The neurological and psychiatric aftermath of COVID-19 has been reported, but adequately assessing the effects of the disease on brain health still remains a challenge. A new preprint analysis, representing one of the most extensive studies of neuropsychiatric symptoms among COVID-19 long-haulers, reports that patients who have been sick with COVID-19 for more than three weeks experience cognitive impairment at least six months after the infection (https://ibn.fm/OSDQx). Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, is poised to provide brain monitoring capabilities to enable clinicians to study the brain wave activity of patients with neurological conditions. 

So-called long COVID has gained momentum over the past year as some patients reported persistent neurological and psychiatric manifestations after their initial infection. The extensive research studied nearly 19,000 adult patients across 51 studies, discussing evidence indicating a potential relationship between COVID-19 and persistent neurological problems. These problems could range from milder symptoms, including headaches, loss of sense of smell and taste, and fatigue, to more severe conditions, including sleep disorders, pain, and cognitive impairment such as brain fog leading to memory loss or difficulty concentrating or making decisions. 

The study found that brain fog affects 20% of Coronavirus long-haulers, while 27% of them reported insomnia, and 24% reported fatigue, both of which researchers believe could stem from neurological issues, although that might not be the only possible cause. Brain fog can have varying impacts on patients; for some, it may be life-altering, while for others can be a minor inconvenience. 

However, diagnosing long-term COVID-19 symptoms remains a challenge as doctors are still learning the underlying mechanisms of how the virus works. For example, without knowing how long these neurological symptoms last, doctors are not able to classify them as neurological disorders or even chronic illnesses. The researchers conclude that doctors will need to track long-haulers to decipher whether they have neurological disorders after they suffered and survived Coronavirus infection.

As a growing body of research indicates, the long-term outlook for COVID-19 patients is still uncertain. Long haul Covid-19 survivors will need ongoing medical help to track and manage the long-term impact of the virus on their health, including brain health. That’s where Brain Scientific’s unique technology can help.

The Company has developed NeuroEEG(TM), a portable, wireless device that can record and display the patient’s electrical brain activity that works together with the NeuroCap(TM) — a hospital-grade disposable EEG headset that comes in sizes for adults and pediatric patients.  Brain Scientific is working on developing another revolutionary technology — Brain E-Tattoo(TM), a minimally invasive four-channel implant or imprint tattoo designed for long-term brain wave activity monitoring even beyond the clinical setting. It can provide access to long-term neurological studies, potentially helping identify root neurological problems. 

More than a year into the pandemic, it remains a challenge to understand the immediate effect of the virus on brain health, with no definite answer regarding the long-term impact either (https://ibn.fm/xNJLl). The scientific world is only starting to truly grasp the effect of COVID-19 on the brain. Brain Scientific appears poised to be a key player providing unparalleled technology that will potentially contribute to providing answers to the most pressing issues in the modern brain diagnostics space. 

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).